Fig. 1.
Detection by RT-PCR of the c-fes mRNA in HL60 cells treated with c-fes ODN. Total cellular RNA was extracted after 5 days of c-fes AS ODN treatment as described in Materials and Methods. The 500-bp amplified c-fes fragment was obtained using the oligonucleotide primers hFES-DP (5′-ACTATGGGCTTCTCTTCCGAGCTG-3′ ) and hFES-RP (5′-TCACGGTCCTTGTCTTTGCTGGCCT-3′ ). The 162-bp human β2-microglobulin fragment, used as a quantitative control, was obtained using the oligonucleotide primers hβ2m-DP (5′-CTCGCGCTACTCTCTCTTTCT-3′ ) and hβ2m-RP (5′-TCCATTCTTCAGTAAGTCAACT-3′ ); Lane 1, DNA mol wt marker VIII (Boehringer); lane 2, untreated HL60 cells; lane 3, HL60 cells treated with the mixture of hFES-S-sj1 and 2; lane 4, HL60 cells treated with the mixture of hFES-IP-sj1 and 2; lane 5, HL60 cells treated with the mixture of hFES-AS-sj1 and 2; lane 6, HL60 cells treated with the mixture of hFES-S1, 2 and 3; lane 7, HL60 cells treated with a mixture of hFES-IP1, 2 and 3; lane 8, HL60 cells treated with hFES-AS1, 2 and 3; lane 9, negative control performed with HL60 cells genomic DNA; lane 10, negative control performed without the cDNA template.

Detection by RT-PCR of the c-fes mRNA in HL60 cells treated with c-fes ODN. Total cellular RNA was extracted after 5 days of c-fes AS ODN treatment as described in Materials and Methods. The 500-bp amplified c-fes fragment was obtained using the oligonucleotide primers hFES-DP (5′-ACTATGGGCTTCTCTTCCGAGCTG-3′ ) and hFES-RP (5′-TCACGGTCCTTGTCTTTGCTGGCCT-3′ ). The 162-bp human β2-microglobulin fragment, used as a quantitative control, was obtained using the oligonucleotide primers hβ2m-DP (5′-CTCGCGCTACTCTCTCTTTCT-3′ ) and hβ2m-RP (5′-TCCATTCTTCAGTAAGTCAACT-3′ ); Lane 1, DNA mol wt marker VIII (Boehringer); lane 2, untreated HL60 cells; lane 3, HL60 cells treated with the mixture of hFES-S-sj1 and 2; lane 4, HL60 cells treated with the mixture of hFES-IP-sj1 and 2; lane 5, HL60 cells treated with the mixture of hFES-AS-sj1 and 2; lane 6, HL60 cells treated with the mixture of hFES-S1, 2 and 3; lane 7, HL60 cells treated with a mixture of hFES-IP1, 2 and 3; lane 8, HL60 cells treated with hFES-AS1, 2 and 3; lane 9, negative control performed with HL60 cells genomic DNA; lane 10, negative control performed without the cDNA template.

Close Modal

or Create an Account

Close Modal
Close Modal